Intraperitoneal Therapy for Ovarian Cancer: Why Has It Not Become Standard?
نویسندگان
چکیده
منابع مشابه
Intraperitoneal therapy for ovarian cancer: why has it not become standard?
T hree randomized, controlled trials have demonstrated substantial improvements in overall survival for patients with advanced ovarian cancer who received chemotherapy via the intraperito-neal (IP) route — injected directly into the peritoneal cavity — compared with those who received it intravenously. Moreover, the National Cancer Institute has recommended that intraperitoneal treatment to be ...
متن کاملHipec in Ovarian Cancer. Why is it Still the Ugly Duckling of Intraperitoneal Therapy?
If one was a surgeon who believed in postoperative systemic chemotherapy, one’s argument would be based on the results of the study GOG 172 (which coincided with a clinical alert from the NCI of the United States in favor of this modality of intraperitoneal treatment after optimal surgery in patients with ovarian cancer) [1]. According to the paper published by Armstrong et al, our relative wou...
متن کاملIntraperitoneal Therapy of Ovarian Cancer.
PURPOSE: This is a review of the rationale for the intraperitoneal administration of antineoplastic agents in the management of ovarian cancer. PATIENTS AND METHODS: Patients have been treated in a number of clinical trials to define the toxicity profile and efficacy of intraperitoneal therapy in this clinical setting. RESULTS: Phase I-II trials have confirmed that a number of cytotoxic and bio...
متن کاملTumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer.
Intraperitoneal chemotherapy prolongs survival of ovarian cancer patients, but its utility is limited by treatment-related complications and inadequate drug penetration in larger tumors. Previous intraperitoneal therapy used the paclitaxel/Cremophor EL (polyethoxylated castor oil) formulation designed for intravenous use. The present report describes the development of paclitaxel-loaded micropa...
متن کاملIntraperitoneal radioimmunotherapy for ovarian cancer.
Twenty-eight patients with assessable residual ovarian cancer after cytoreductive surgery and chemotherapy received intraperitoneal I-131 labelled monoclonal antibodies. There was no response in eight patients with tumour nodules greater than 2 cm, a partial response in two of the 15 patients with tumour nodules less than 2 cm, and a complete response in three of the other five patients with po...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: JNCI: Journal of the National Cancer Institute
سال: 2009
ISSN: 0027-8874,1460-2105
DOI: 10.1093/jnci/djp151